Saturna Capital CORP - DENALI THERAPEUTICS INC ownership

DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 213 filers reported holding DENALI THERAPEUTICS INC in Q2 2021. The put-call ratio across all filers is 0.25 and the average weighting 0.4%.

Quarter-by-quarter ownership
Saturna Capital CORP ownership history of DENALI THERAPEUTICS INC
ValueSharesWeighting
Q4 2021$223,000
-11.5%
5,0000.0%0.00%
-20.0%
Q3 2021$252,000
-35.7%
5,0000.0%0.01%
-37.5%
Q2 2021$392,000
+37.1%
5,0000.0%0.01%
+33.3%
Q1 2021$286,000
-51.2%
5,000
-28.6%
0.01%
-53.8%
Q4 2020$586,000
+133.5%
7,0000.0%0.01%
+116.7%
Q3 2020$251,0007,0000.01%
Other shareholders
DENALI THERAPEUTICS INC shareholders Q2 2021
NameSharesValueWeighting ↓
Crestline Management, LP 7,460,732$240,012,00028.78%
Casdin Capital, LLC 1,500,000$48,255,0002.16%
Flagship Pioneering Inc. 2,619,968$84,284,0001.98%
INTERNATIONAL BIOTECHNOLOGY TRUST PLC 38,000$8,192,0001.85%
Yiheng Capital Management, L.P. 1,014,684$32,642,0001.49%
SECTORAL ASSET MANAGEMENT INC 207,100$6,662,0001.18%
Artal Group S.A. 600,000$19,302,0000.81%
GILDER GAGNON HOWE & CO LLC 2,619,217$84,260,0000.78%
Temasek Holdings (Private) Ltd 5,369,487$172,736,3970.73%
BRANDYWINE MANAGERS, LLC 9,601$309,0000.53%
View complete list of DENALI THERAPEUTICS INC shareholders